Radiofrequency Ablation Devices Market Size

Global Radiofrequency Ablation Devices Market Overview

The Radiofrequency Ablation Devices Market Size was valued at USD 4.76 Billion in 2023. The Global Radiofrequency Ablation Devices industry is projected to grow from USD 5.37 Billion in 2024 to USD 13.05 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.38% during the forecast period (2024 - 2032). It uses thermal energy to achieve targeted tissue destruction. Radiofrequency ablation (RFA) is a minimally invasive procedure appropriate for patients with cardiac diseases. For instance, atrial fibrillation (AF), atrial flutter, cardiac arrhythmias, cancer, and pain management. It provides high efficacy, ease of use, and safety, becoming the most preferred method. The process is being increasingly used to treat many diseases, such as cancer and cardiac arrhythmia.

Radiofrequency Ablation Devices Market Trends

The growing geriatric population is also a reason for the market growth. Recently the growing economy and strong insurance policies will increase the market growth. The increasing number of lung cancer cases in the American region keeps the market growing. Although the number of cardiac patients is rising, awareness is also increasing of the disease. The poor economy and less per capita income, for some reason, could hinder market growth. The rise in government funds for the healthcare sector and developing economies in several countries will improve the market globally. Some of the side effects associated with the system for pain management procedures are discomfort, swelling, and tissue charring.

Radiofrequency Ablation Devices Market Segment Insights

The radiofrequency ablation devices market is segmented on the basis of type, application, and region.

Radiofrequency Ablation Devices Type Insights

On the basis of the type, the radiofrequency ablation devices market is segmented into Unipolar radiofrequency ablation and Bipolar radiofrequency ablation. 

Radiofrequency Ablation Devices Application Insights

By application, the global radiofrequency ablation devices  market is categorized into Surgical Oncology, Cardiology and Cardiac Rhythm Management, Gynecology, Cosmetology, Pain Management

Radiofrequency Ablation Devices Regional Insights

The Americas dominates the global market for radiofrequency ablation devices owing a growing number of lung cancer cases like, Non-Small Cell Lung Cancer (NSCLC) which is the most common type of lung cancer, accounting for 80-85% of all lung cancer cases. It is generally a slow growing and spreading as compared to small cell lung cancer (SCLC). Small cell lung cancer used to account for 12-13% of lung cancers. However, there has been a shift from NSCLC to SCLC in recent years which has propelled the market growth of the radiofrequency ablation devices.

It was estimated that Europe stood second in the radiofrequency ablation devices market.

Asia-Pacific was the fastest growing region for the market of radiofrequency ablation devices in 2021. Factors such as increasing awareness of the cardiac disease, growing healthcare industries, and the development of various treatment methods for gynecology and cosmetology drives the market in this region.

On the other hand, the Middle East and Africa holds the least market share in the radiofrequency ablation devices. The presence of poor economies and low per capita income, especially within the African region make the market to lag within the region. A majority of the market share within this region is estimated to be held by the Middle East due to increasing government funding in the healthcare for healthcare, and presence of developed economies like UAE, Kuwait, Dubai, and others.

Some of the key players in the global radiofrequency ablation devices  market are 

• Boston Scientific Corporation


• Medtronic Inc


• Stryker


• Cosman Medical, Inc


• Jude medical


• Smith & Nephew


• Johnson & Johnson (J&J) Services, LLC


• Angiodynamics


• RF Medical Co Ltd


• AtriCure, Inc.


• Others

Recent Development

November 2023, Medtronic announces the launch of its new Symplicity System, a radiofrequency ablation device for the treatment of atrial fibrillation (AFib). The Symplicity System is designed to provide physicians with a safe and effective way to treat patients with AFib.Boston Scientific announces the launch of its new CoolTouch XP Ablation Catheter, a radiofrequency ablation device for the treatment of cardiac arrhythmias. The CoolTouch XP Ablation Catheter is designed to provide physicians with a more precise and controlled way to ablate cardiac tissue.Abbott Laboratories announces the launch of its new Navistar Ablation System, a radiofrequency ablation device for the treatment of ventricular tachycardia (VT). The Navistar Ablation System is designed to provide physicians with a more effective way to treat patients with VT.

September 2023, KARL STORZ GmbH & Co. KG and Google Cloud announce a partnership to develop new AI-powered radiofrequency ablation solutions. The partnership will combine KARL STORZ's expertise in radiofrequency ablation devices with Google Cloud's expertise in AI to develop new solutions that can improve patient care and outcomes.Smith & Nephew plc announces the launch of its new NAVISENT ENT navigation system. The NAVISENT system is designed to provide surgeons with real-time 3D visualization of the patient's anatomy during radiofrequency ablation procedures.

May 2022, A team of researchers from Huazhong University of Science and Technology (HUST) has invented an approach using a radiofrequency ablation device designed to heat only the cancer tissue while leaving healthy tissue unharmed.

April 2022

IQWiG has now published its assessment for two 137h procedures commissioned with the G-BA. The first one is endoscopic ultrasound-guided 32P microparticle implantation for unresectable, locally advanced pancreatic tumors. The other is "transcervical radiofrequency ablation with intrauterine ultrasound guidance for uterine fibroids."

A leading innovator in surgical treatments and therapies for atrial fibrillation left atrial appendage management and post-operative pain management named AtriCure; Inc announced that it had launched the EnCompass Clamp®, a part of the Isolator Synergy™ Ablation System in the United States.

Research Methodology

Market Research Future research is conducted by industry experts who offer insights into industry structure, market segmentation, assessment, Competitive Landscape (CL), penetration, as well as on emerging trends. Besides primary interviews (~ 80%) and secondary research (~ 20%), their analysis is based on their years of professional expertise in respective industries. Our analysts also predict where the market will be headed in the next five to ten years, by analyzing historical trends and current market positions. Furthermore, the varying trends of segments and categories geographically presented are studied and are estimated based on the primary and secondary research.

• Primary Research

Extensive primary research was conducted to gain a deeper insight into the market and industry performance. In this particular report, we have conducted primary surveys (interviews) with key level executives (VPs, CEOs, Marketing Directors, Business Development Managers, and many more) of major players who are active in the market. In addition to analyzing the current and historical trends, our analysts predict where the market is headed, over the next five to ten years.

• Secondary Research

Secondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and commercial study of the radiofrequency ablation devices market. It was also used to obtain key information about major players, market classification, and segmentation according to industry trends, geographical markets, and developments related to the market and perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, SEC filings, journals, white papers, corporate presentations, company web sites, an international organization of chemical manufacturers, some paid databases, and many others.

Intended Audience

• Government and private laboratories


• Research and Development (R&D) companies


• Medical research laboratories


• Market research and consulting service providers


• Biotechnology companies

Radiofrequency Ablation Devices Market Segmentation

Radiofrequency Ablation Devices Underlying Cause Outlook

• Unipolar radiofrequency ablation


• Bipolar radiofrequency ablation

Radiofrequency Ablation Devices Application Outlook

• Surgical Oncology


• Cardiology and Cardiac Rhythm Management


• Gynecology


• Cosmetology


• Pain Management


• Others